Obinutuzumab, acalabrutinib, and venetoclax, after an optional debulking with bendamustine in relapsed or refractory chronic lymphocytic leukaemia (CLL2-BAAG): a multicentre, open-label, phase 2 trial

Paula Cramer, Moritz Fürstenau, Sandra Robrecht, Adam Giza, Can Zhang, Anna‐Maria Fink, Kirsten Fischer, Petra Langerbeins, Othman Al‐Sawaf, Eugen Tausch, Christof Schneider, Johannes Schetelig, Peter Dreger, Sebastian Böttcher, Karl‐Anton Kreuzer, Anke Schilhabel, Matthias Ritgen, Monika Brüggemann, Michael Kneba, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek